Characterization of the Response to Secukinumab in Plaque Psoriasis Using Novel Immunologic and Genetic Profiling

Trial Profile

Characterization of the Response to Secukinumab in Plaque Psoriasis Using Novel Immunologic and Genetic Profiling

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 May 2017

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Psoriasis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 May 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Oct 2018.
    • 29 Jul 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top